Detail akcie Bsch+Lmb Rg Reg S online

Business Summary: Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Bausch + Lomb Corp revenues increased 5% to $3.7B. Net loss decreased 4% to $302M. Revenues reflect Vision CareConsumer Health Care segment increase of 6% to $2.15B, Surgical segment increase of 5% to $645M. Lower net loss reflects Acquisition Cost of Group Companies decrease from $2M (expense) to $50M (income), Amortization of intangible assets decrease of 8% to $202M (expense).